The 36-month beta value for EBS is at 1.21. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for EBS is 50.09M, and currently, shorts hold a 11.77% of that float. The average trading volume for EBS on April 26, 2024 was 3.00M shares.
EBS) stock’s latest price update
The stock of Emergent Biosolutions Inc (NYSE: EBS) has decreased by -10.55 when compared to last closing price of 2.18. Despite this, the company has experienced a 4.84% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-22 that GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024.
EBS’s Market Performance
EBS’s stock has risen by 4.84% in the past week, with a monthly drop of -20.08% and a quarterly rise of 4.84%. The volatility ratio for the week is 10.82% while the volatility levels for the last 30 days are 8.72% for Emergent Biosolutions Inc The simple moving average for the last 20 days is -11.10% for EBS stock, with a simple moving average of -38.82% for the last 200 days.
Analysts’ Opinion of EBS
Many brokerage firms have already submitted their reports for EBS stocks, with The Benchmark Company repeating the rating for EBS by listing it as a “Buy.” The predicted price for EBS in the upcoming period, according to The Benchmark Company is $5 based on the research report published on March 07, 2024 of the current year 2024.
EBS Trading at -19.37% from the 50-Day Moving Average
After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.08% of loss for the given period.
Volatility was left at 8.72%, however, over the last 30 days, the volatility rate increased by 10.82%, as shares sank -24.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.64% upper at present.
During the last 5 trading sessions, EBS rose by +4.84%, which changed the moving average for the period of 200-days by -73.21% in comparison to the 20-day moving average, which settled at $2.16. In addition, Emergent Biosolutions Inc saw -18.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EBS starting from Zoon Kathryn C, who sale 1,830 shares at the price of $8.35 back on Jun 02 ’23. After this action, Zoon Kathryn C now owns 49,971 shares of Emergent Biosolutions Inc, valued at $15,280 using the latest closing price.
Zoon Kathryn C, the Director of Emergent Biosolutions Inc, sale 1,700 shares at $8.38 during a trade that took place back on May 25 ’23, which means that Zoon Kathryn C is holding 51,801 shares at $14,246 based on the most recent closing price.
Stock Fundamentals for EBS
Current profitability levels for the company are sitting at:
- -0.69 for the present operating margin
- 0.31 for the gross margin
The net margin for Emergent Biosolutions Inc stands at -0.72. The total capital return value is set at -0.61. Equity return is now at value -74.34, with -30.28 for asset returns.
Based on Emergent Biosolutions Inc (EBS), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at -0.24. The debt to equity ratio resting at 1.33. The interest coverage ratio of the stock is -8.2.
Currently, EBITDA for the company is -42.9 million with net debt to EBITDA at -8.71. When we switch over and look at the enterprise to sales, we see a ratio of 0.83. The receivables turnover for the company is 5.5for trailing twelve months and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.04.
Conclusion
In conclusion, Emergent Biosolutions Inc (EBS) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
